Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis

V. Bhandari; A. Kulshrestha; D.K. Deep; O. Stark; V.K. Prajapati; V. Ramesh; S. Sundar; G. Schönian; J.C. Dujardin; P. Salotra

doi:10.1371/journal.pntd.0001657

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis

V. Bhandari, A. Kulshrestha, D.K. Deep, O. Stark, V.K. Prajapati, V. Ramesh, S. Sundar, G. Schönian, J.C. Dujardin, P. Salotra

Molecular Parasitology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

78 Downloads (Pure)

Original language	English
Journal	PLoS Neglected Tropical Diseases
Volume	6
Issue number	5
Pages (from-to)	e1657
ISSN	1935-2727
DOIs	https://doi.org/10.1371/journal.pntd.0001657
Publication status	Published - 2012

Keywords

Protozoal diseases
Visceral
Leishmaniasis
Kala azar
Leishmania donovani
Vectors
Sandflies
Phlebotomus argentipes
Disease progression
Drug susceptibility
In vitro
Isolation
Treatment
Miltefosine
Relapses
Tolerance
Mutations
Amastigotes
India
Asia-South

Access to Document

10.1371/journal.pntd.0001657

2012pntde1657Final published version, 176 KB

Cite this

Bhandari, V., Kulshrestha, A., Deep, D. K., Stark, O., Prajapati, V. K., Ramesh, V., Sundar, S., Schönian, G., Dujardin, J. C., & Salotra, P. (2012). Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis. PLoS Neglected Tropical Diseases, 6(5), e1657. https://doi.org/10.1371/journal.pntd.0001657

@article{da462bec128646038b92143ae2f5280a,

title = "Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis",

keywords = "Protozoal diseases, Visceral, Leishmaniasis, Kala azar, Leishmania donovani, Vectors, Sandflies, Phlebotomus argentipes, Disease progression, Drug susceptibility, In vitro, Isolation, Treatment, Miltefosine, Relapses, Tolerance, Mutations, Amastigotes, India, Asia-South",

author = "V. Bhandari and A. Kulshrestha and D.K. Deep and O. Stark and V.K. Prajapati and V. Ramesh and S. Sundar and G. Sch{\"o}nian and J.C. Dujardin and P. Salotra",

note = "ITG-B9A; DBM; U-MOLPAR; JIF; DOI; PDF; E-only; DSPACE",

year = "2012",

doi = "10.1371/journal.pntd.0001657",

language = "English",

volume = "6",

pages = "e1657",

journal = "PLoS Neglected Tropical Diseases",

issn = "1935-2727",

publisher = "Public Library of Science",

number = "5",

}

Bhandari, V, Kulshrestha, A, Deep, DK, Stark, O, Prajapati, VK, Ramesh, V, Sundar, S, Schönian, G, Dujardin, JC & Salotra, P 2012, 'Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis', PLoS Neglected Tropical Diseases, vol. 6, no. 5, pp. e1657. https://doi.org/10.1371/journal.pntd.0001657

TY - JOUR

T1 - Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala azar dermal leishmaniasis

AU - Bhandari, V.

AU - Kulshrestha, A.

AU - Deep, D.K.

AU - Stark, O.

AU - Prajapati, V.K.

AU - Ramesh, V.

AU - Sundar, S.

AU - Schönian, G.

AU - Dujardin, J.C.

AU - Salotra, P.

N1 - ITG-B9A; DBM; U-MOLPAR; JIF; DOI; PDF; E-only; DSPACE

PY - 2012

Y1 - 2012

KW - Protozoal diseases

KW - Visceral

KW - Leishmaniasis

KW - Kala azar

KW - Leishmania donovani

KW - Vectors

KW - Sandflies

KW - Phlebotomus argentipes

KW - Disease progression

KW - Drug susceptibility

KW - In vitro

KW - Isolation

KW - Treatment

KW - Miltefosine

KW - Relapses

KW - Tolerance

KW - Mutations

KW - Amastigotes

KW - India

KW - Asia-South

U2 - 10.1371/journal.pntd.0001657

DO - 10.1371/journal.pntd.0001657

M3 - A1: Web of Science-article

C2 - 22629478

SN - 1935-2727

VL - 6

SP - e1657

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

IS - 5

ER -